Home / Products / Formulations / Svizera Healthcare /Manav Care / Ambril Plus


        Each 5 ml of AMBRIL PLUS contains :
        Levosalbutamol sulphate ……5 mg
Ambroxol HCL………………15 mg
Guaiphenesin ………………50 mg
        Therapeutic Indications & Usage
        In management of cough associated with
  • Bronchial Asthma
  • Bronchitis
  • COPD
  • RTI
        Hypersensitivity to any of the components of the AMBRIL PLUS formulations
        Precautions & Warnings
        Potentially serious hypokalemia may result from beta 2- agonist therapy. Levosalbutamol, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure and/or symptoms. Although such effects are uncommon after administration of Levosalbutamol (in AMBRIL PLUS) at recommended doses, if they occur, the drug may need to be discontinued. Oral Levosalbutamol (in AMBRIL PLUS) should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias or hypertension
        Guaiphesin ( in AMBRIL PLUS) if taken in Excessive Dosage ,Emesis may result from doses larger than those required for expectorant action, but GI upset at ordinary dosage is rare
        Adverse Reactions
        AMBRIL PLUS may cause Potentially serious hypokalaemia as a result from beta 2 -agonist therapy. This effect may be potentiated by hypoxia. Particular caution is advised in severe asthma, with monitoring of serum potassium levels. Other side effects such as palpitation, fine tremors of the skeletal muscle (particularly the hand) and muscle cramps may occur. The other likely side effects are gastrointestinal disturbances such as nausea, vomiting, burning substernal or epigastric pain and diarrhoea. In some cases nervousness, headache, dizziness, fatigue and sleeplessness may occur.
        Drug Interaction
        Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with Levosalbutamol (in AMBRIL PLUS). If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Beta-blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists such as Levosalbutamol (in AMBRIL PLUS), but may also produce severe bronchospasm in asthmatic patients. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, use of beta-adrenergic blocking agents could be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalaemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists. Hence, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics. Digoxin: Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of racemic salbutamol, hence it is advisable to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and Levosalbutamol (in AMBRIL PLUS). Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Levosalbutamol (in AMBRIL PLUS)should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of Levosalbutamol (in AMBRIL PLUS)on the vascular system may be potentiated.
        Recommended Dosage & Administration
        Oral Administration
        Adult – as prescribed
        Children - as prescribed
        AMBRIL PLUS : Bottle pack of 100ml


"Maneesh" Pharmaceuticals   |  Manufacturing Excellence  |   International Presence  |  Products
"Maneesh" for Doctors  |  Our Team  |  For the Patients  
Contact Us  |  Feedback  |  Site Map  | Search Maneesh